Enzymotec has announced that clinical trials for its lipid-based ingredient line for infant nutrition yielded positive results.These large-scale clinical research trials were conducted on newborn term infants in several institutes globally.
The clinical trial plan is a part of the company's strategy to develop and market its products,which mimic the vital lipids found in mother's milk,such as triglyceride,phospholipids and long-chain polyunsaturated fatty acids(LCPUFA).
Enzymotec Infant Nutrition R&D director Yael Lifshitz said the clinical trials plan represents Enzymotec's ongoing dedication to study the special characteristics of human milk and demonstrate its lipid-based ingredients'health benefits on various infant populations.
"We developed this innovative ingredient and educated the premium infant formula market over the last several years.Enzymotec invested 10%of its revenue in research and development-a percentage considered among the highest in the industry,"Lifshitz added.
In the coming months,the company plans to publish four new scientific articles on its lipid-based ingredients for infant nutrition in peer-reviewed journals.
Enzymotec is a research-based biotech company that develops,manufactures and markets innovative lipid-based,bio-functional ingredients and final products.The Enzymotec Infant Nutrition division develops lipid compositions that mimic human milk fat to facilitate healthy infant development.
